–First-in-Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GFB-887, a Targeted Podocyte-protective Therapeutic for the treatment of Focal Segmental Glomerulosclerosis, Treatment-resistant Minimal Change Disease and Diabetic...
A double-blind, placebo-controlled trial aimed at assessing efficacy and safety of leriglitazone, up-regulated CNS disorders in Friedreich’s Ataxia patients Image Courtesy: Minoryx therapeutics Minoryx Therapeutics, a company specializing in the development of new...
CytoDyn is also coordinating with an international public health agency to fully fund an HIV prevention study with leronlimab CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5...
– Enrollment in the pheNIX Study Marks First Gene Therapy Clinical Trial for PKU – BEDFORD, Mass., June 10, 2019 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has commenced enrollment...
RISE researchers present Adult Medication Study results at the ADA’s Scientific Sessions and share the first direct comparison for youth and adult studies In a study measuring Beta-cell (β-cell) function in adults with impaired glucose tolerance (IGT) or newly...
Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced dosing of the first subject in a Phase 1b trial of a topical ocular...
Email
Text